AKBA — Stock Film
STOCK FILMSCENE 1/11AKBA · $0.92
Stock Expert AI presents
AKBA
Akebia Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Akebia Therapeutics, Inc. A quick introduction.

On the stock market since 2014, it operates in the world of health and science. It has 181 employees. Now — the numbers.

on the stock market since 2014
181 employees
$391.1M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
96%License Collaboration and Other Revenue
License Collaboration and Other Revenue 96%Supply Agreement 3%License Collaboration and Other Revenue, Royalties 1%
96% of all revenue comes from a single line: License Collaboration and Other Revenue.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $216.3M
At this pace, that money lasts about 34.6 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
71
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
10
very weak

Clearly below the class average.

VALUATION
74
strong

Clearly above the class average — a step short of the very top.

GROWTH
78
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
20
very weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales are holding up

The company sells $236.2M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 54 buys and 29 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small scale, thin loss

A loss of $5.3M against $236.2M in annual sales.

2
THE RISKS · 2/2
Trading under $1

The stock sits at $0.92. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, AKBA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AKBA is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film